Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan
详细信息 查看全文
- 作者：Minako Iida (1) (2)
Takahiro Fukuda (3)
Kazuhiro Ikegame (4)
Satoshi Yoshihara (4)
Hiroyasu Ogawa (4)
Shuichi Taniguchi (5)
Akiyoshi Takami (6)
Yasunobu Abe (7)
Masayuki Hino (8)
Tetsuya Etou (9)
Yasunori Ueda (10)
Toshiaki Yujiri (11)
Toshimitsu Matsui (12)
Atsuo Okamura (12)
Junji Tanaka (13)
Yoshiko Atsuta (1)
Yoshihisa Kodera (2)
Ritsuro Suzuki (1) - 关键词：Mycophenolate mofetil (MMF) ; Allogeneic stem cell transplantation ; GVHD
- 刊名：International Journal of Hematology
- 出版年：2011
- 出版时间：April 2011
- 年：2011
- 卷：93
- 期：4
- 页码：523-531
- 全文大小：435KB
- 参考文献：1. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol. 2001;29:259-7. CrossRef
2. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-2.
3. Martin PJ, Carpenter PA, Sanders JE, Flowers ME. Diagnosis and clinical management of chronic graft-versus-host disease. Int J Hematol. 2004;79:221-. CrossRef
4. Basara N, Blau WI, Kiehl MG, Romer E, Rudolphi M, Bischoff M, et al. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant Proc. 1998;30:4087-. CrossRef
5. Basara N, Blau WI, Kiehl MG, Schmetzer B, Bischoff M, Kirsten D, et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant. 2000;14:121-. CrossRef
6. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M, Kirsten D, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant. 1998;22:61-. CrossRef
7. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;34:621-. CrossRef
8. Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation. 1999;67:499-04. CrossRef
9. Busca A, Saroglia EM, Lanino E, Manfredini L, Uderzo C, Nicolini B, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation. Bone Marrow Transplant. 2000;25:1067-1. CrossRef
10. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol. 2004;73:56-1. CrossRef
11. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. 1999;24:517-0. CrossRef
12. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005;11:495-05. CrossRef
13. Neumann F, Graef T, Tapprich C, Vaupel M, Steidl U, Germing U, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant. 2005;35:1089-3. CrossRef
14. Okamura A, Yamamori M, Shimoyama M, Kawano Y, Kawano H, Kawamori Y, et al. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2008;88:104-0. CrossRef
15. Takami A, Mochizuki K, Okumura H, Ito S, Suga Y, Yamazaki H, et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol. 2006;83:80-. CrossRef
16. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269-4. CrossRef
17. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter S, Difronzo N, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009;114:511-. CrossRef
18. Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002;8:32-. CrossRef
19. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-3. CrossRef
20. Furlong T, Martin P, Flowers ME, Carnevale-Schianca F, Yatscoff R, Chauncey T, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant. 2009;44:739-8. CrossRef
21. Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-000). Blood. 2003;102:1541-. CrossRef
22. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113:5074-2.
23. Arai S, Vogelsang GB. Management of graft-versus-host disease. Blood Rev. 2000;14:190-04. CrossRef
24. Bornhauser M, Thiede C, Schuler U, Platzbecker U, Freiberg-Richter J, Helwig A, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant. 2000;26:119-5. CrossRef
25. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol. 2005;84:681-. CrossRef
26. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-.
27. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998;92:2303-4. - 作者单位：Minako Iida (1) (2)
Takahiro Fukuda (3)
Kazuhiro Ikegame (4)
Satoshi Yoshihara (4)
Hiroyasu Ogawa (4)
Shuichi Taniguchi (5)
Akiyoshi Takami (6)
Yasunobu Abe (7)
Masayuki Hino (8)
Tetsuya Etou (9)
Yasunori Ueda (10)
Toshiaki Yujiri (11)
Toshimitsu Matsui (12)
Atsuo Okamura (12)
Junji Tanaka (13)
Yoshiko Atsuta (1)
Yoshihisa Kodera (2)
Ritsuro Suzuki (1)
1. Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine, Nagoya, Japan
2. Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, 21, Karimata, Yazako, Nagakute-cho, Aichi-gun, Aichi, 480-1195, Japan
3. Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
4. Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
5. Department of Hematology, Toranomon Hospital, Tokyo, Japan
6. Department of Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
7. Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyusyu University, Fukuoka, Japan
8. Department of Hematology, Osaka City University Graduate School of Medicine, Osaka, Japan
9. Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan
10. Department of Hematology, Kurashiki Central Hospital, Okayama, Japan
11. Third Department of Internal Medicine, Yamaguchi University School of Medicine, Yamaguchi, Japan
12. Department of Hematology, Kobe University Graduate School of Medicine, Hyogo, Japan
13. Department of Hematology, Hokkaido University Hospital, Sapporo, Japan
文摘
We evaluated the use of mycophenolate mofetil (MMF) after hematopoietic stem cell transplantation (HSCT) in Japan from 1999 to 2008. MMF was administered to 301 patients, including 157 for the prevention of graft-versus-host disease (GVHD), 94 for the treatment of acute GVHD and 50 for the treatment of chronic GVHD. The three most common doses were 500?mg twice daily, 250?mg three times daily and 1,000?mg twice daily, given to 63, 54 and 45 patients, respectively. The incidence of grade II–IV acute GVHD was 30.0% and grade III–IV was 20.0% in the GVHD prevention group. Among treated patients, disappearance or improvement of subjective symptoms occurred in 57.0% of acute GVHD patients and in 52.0% of chronic GVHD patients. With regard to safety, the following major adverse events (grade 3 or more) were recorded: 31 infections, 31 neutropenia, 28 thrombocytopenia, 25 diarrhea and 1 renal disorder. A total of 116 patients developed grade 3 or 4 adverse events, but 79 were successfully treated with supportive treatment. Thus, our findings suggest that MMF is safe and effective for the prevention and treatment of GVHD in patients who have received an allogeneic stem cell transplant.